Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
CTEV — Claritev Corporation
NYSE
FULL STOCK PAGE →

CTEV Q4 2025 Earnings Call Summary

FEB 23, 2026 2 MIN READ
REVENUE
$246.6M +0.2%
NET MARGIN
-32.7% -4.3 PTS
EPS
-$4.88 -15.4%
FREE CASH FLOW
$36.4M +322.5%

1Key Financial Results and Metrics

Q4 Revenue: $246.6 million, up 6.2% year-over-year.

Full Year Revenue: $965.4 million, an increase of 3.7%.

Adjusted EBITDA: Q4 at $151.3 million (61.4% margin), full year at $602.6 million (4.5% increase).

Free Cash Flow: Q4 generated $36.4 million; full year ended with a use of $12.3 million, significantly better than the initial forecast of a $70 million use.

Bookings: Record $23 million in Q4, contributing to $67 million in annual ACV booked, with a 30% increase in deals over $100,000.

2Strategic Updates and Business Highlights

Vision 2030: Emphasis on building a sustainable healthcare technology company focused on affordability and transparency.

Digital Transformation: Progressing well, with the introduction of new solutions like the Network Builder, enhancing network creation efficiency.

Market Expansion: Acquired 30 new clients across various verticals, including international expansion in the Middle East.

AI Strategy: Strong focus on leveraging AI to improve healthcare processes and client outcomes, with plans to detail this further at the Investor Day on March 16.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected between $980 million and $1 billion, representing 2% to 4% growth over 2025.

Adjusted EBITDA Guidance: Projected at $605 million to $615 million, with margins of 61% to 62%.

ACV Growth: Anticipating strong double-digit growth in ACV bookings for 2026, with revenue growth expected to ramp in the second half of the year.

4Bad News, Challenges, or Points of Concern

One-Time Revenue Impact: Q4 included $5 million in non-recurring revenue from the P&C business, which will not repeat in 2026, affecting growth comparisons.

Operational Costs: Transitioning some capitalized costs to OpEx as the company moves to cloud computing, which may impact adjusted EBITDA margins.

High Net Leverage: Ended the year with a net leverage of 7.7x, although improved from previous levels.

Market Pressures: Ongoing concerns about medical inflation and out-of-network claims volume, which could impact future revenue models.

5Notable Q&A Insights

Audio Issues: The call experienced technical difficulties, leading to a brief pause and a decision to cut the call early, directing participants to submit questions via email.

Client Trust and Relationships: Emphasis on maintaining strong client relationships and trust as a competitive advantage, particularly in the context of AI integration.

Focus on Cash Flow: Management reiterated the importance of improving free cash flow and adjusted cash conversion as key metrics moving forward. This summary encapsulates the essential aspects of Claritev's Q4 2025 earnings call, highlighting both achievements and challenges as the company positions itself for future growth.

SOURCE: Q4 2025 EARNINGS CALL TRANSCRIPT